IMRN - Immuron to host Live Virtual Event | Benzinga
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT.
TRAVELAN® BOUND FOR PHASE 3 CLINICAL TRIALS
Exploring Immuron's Positive Phase 2 Travelan® Results and Upcoming Phase 3 Trial
We'd like to invite shareholders and potential investors to Immuron Ltd's (ASX:IMC) / (NASDAQ:IMRN) upcoming Virtual Symposium!
Join Steve Lydeamore, CEO Immuron, Dr. Joanne Casey, R&D Manager Immuron, and Dr. Jerry Kanellos, CSO Immuron, as they explore the Company's positive Phase 2 Travelan® (IMM-124E) results, upcoming Phase 3 trial, proprietary technology behind Immuron's success, and more.
Last month, Immuron, a globally integrated biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, reported positive interim topline results from its Phase 2 trial of Travelan. The study's findings indicated protective efficacy against enterotoxigenic Escherichia coli (ETEC)-induced diarrhea, a common and debilitating condition affecting travelers, and adds additional data to the established excellent safety and tolerability profile of Travelan. Remarkably, there was a 83.3% reduction in the number of participants requiring early antibiotic treatment compared to placebo and 100% of participants requiring IV fluids were in the placebo group.
Immuron's proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal tract and can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces.
In the clinical study, predominantly funded by a US$3.43 million grant from the US Department of Defense, Travelan demonstrated a 36.4% reduction in cases of moderate to severe diarrhea and a remarkable 66.7% efficacy against severe diarrhea instances, compared to placebo. This Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study.
With 30% to 70% of travelers experiencing traveler's diarrhea, according to the CDC, the traveler's diarrhea treatment market is large and growing at a CAGR of ~7%. According to a Lumanity Opportunity Assessment for IMM-124E, based on the estimated market size and pricing, the base case yearly revenue in USA for IMM-124E is projected at US$102M.
Immuron will now proceed to hold an end of Phase 2 meeting with the FDA to discuss the pivotal Phase 3 registration strategy as well as explore funding for Phase 3. By merely entering Phase 3, Immuron will be among an exclusive list of ASX biotech stocks in Phase 3.
At this webinar, you can expect an insightful exploration into the results, upcoming milestones to come from Immuron, and other research and development ...